Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04526704
Registration number
NCT04526704
Ethics application status
Date submitted
21/08/2020
Date registered
26/08/2020
Date last updated
8/08/2023
Titles & IDs
Public title
Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
Query!
Scientific title
A Phase 4, Multicenter Study to Evaluate Discontinuation and Re-Treatment in Subjects With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
Query!
Secondary ID [1]
0
0
2020-000192-20
Query!
Secondary ID [2]
0
0
PL3397-A-U4003
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
PLX3397
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Tenosynovial Giant Cell Tumor
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Bone
Query!
Cancer
0
0
0
0
Query!
Other cancer types
Query!
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Pexidartinib
Experimental: Treatment Continuation Cohort - Previously-treated participants with TGCT continuing their current dose of pexidartinib treatment.
Experimental: Treatment-Free/Re-Treatment Cohort - Previously-treated participants with TGCT who discontinue pexidartinib treatment (Treatment-Free Period) and resume pexidartinib treatment at dose at completion of prior study (Re-Treatment Period).
Treatment: Drugs: Pexidartinib
200 mg capsules administered orally twice daily on an empty stomach (at least 1 hour before or at least 2 hours after a meal or snack)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Proportion of Treatment-Free Participants at 12 Months
Query!
Assessment method [1]
0
0
This is the proportion of participants who remain treatment-free at Month 12.
Query!
Timepoint [1]
0
0
Baseline up to 12 months after last participant enrolled in Cohort
Query!
Primary outcome [2]
0
0
Proportion of Treatment-Free Participants at 24 Months
Query!
Assessment method [2]
0
0
This is the proportion of participants who remain treatment-free at Month 24.
Query!
Timepoint [2]
0
0
Baseline up to 24 months after last participant enrolled in Cohort
Query!
Secondary outcome [1]
0
0
Change From Baseline in PROMIS Physical Function Scale during the Treatment-Free Period
Query!
Assessment method [1]
0
0
The PROMIS Physical Function Scale is based on a 5-point rating scale, where 1 is unable to do and 5 is without any difficulty.
Query!
Timepoint [1]
0
0
Baseline and then assessed every 3 months until end of study, up to approximately 24 months
Query!
Secondary outcome [2]
0
0
Change From Baseline in EQ-5D-5L during the Treatment-Free Period
Query!
Assessment method [2]
0
0
The EQ-5D-5L questionnaire will ask the participant to describe their health in the areas of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The overall health is rated on a scale from 0 to 100, where 0 is worst health you can imagine and 100 is best health you can imagine.
Query!
Timepoint [2]
0
0
Baseline and then assessed every 3 months until end of study, up to approximately 24 months
Query!
Secondary outcome [3]
0
0
Number of Participants Who Reported Treatment-Emergent Adverse Events (TEAEs) during the Treatment-free Period
Query!
Assessment method [3]
0
0
TEAEs are defined as new Adverse Events or pre-existing conditions that worsen in CTCAE grade after the first dose of study drug and up to 30 days after last dose of study drug.
Query!
Timepoint [3]
0
0
Baseline up to 30 days after the start of re-treatment or end of study (whichever occurs first), up to approximately 24 months
Query!
Secondary outcome [4]
0
0
Percentage of Participants Achieving Tumor Response as assessed by Magnetic Resonance Imaging (MRI)
Query!
Assessment method [4]
0
0
Individual participant outcomes by tumor volume score (TVS) will be classified according to the following criteria via RECIST: Complete response (CR), Lesion completely gone; Partial response (PR), =50% decrease in volume score relative to baseline; Progressive disease (PD), =30% increase in volume relative to lowest score during the study whether at baseline or some other visit; Stable disease (SD), Does not meet any of the prior criteria based on score during study.
Query!
Timepoint [4]
0
0
Baseline and assessed every 6 months (treatment continuation) or every 3 months (treatment-free/re-treatment), up to approximately 24 months
Query!
Secondary outcome [5]
0
0
Number of Participants Who Reported TEAEs during the Re-treatment Period
Query!
Assessment method [5]
0
0
TEAEs are defined as new Adverse Events or pre-existing conditions that worsen in CTCAE grade after the first dose of study drug and up to 30 days after last dose of study drug.
Query!
Timepoint [5]
0
0
Start of re-treatment up to 30 days after end of study, up to approximately 24 months
Query!
Eligibility
Key inclusion criteria
- Currently enrolled and on pexidartinib treatment in one of the following studies:
Study PLX108-10 (ENLIVEN), Study PLX108-01, Study PL3397-A-A103 or Study
PL3397-A-U126.
- Willing and able to complete the PROMIS Physical Function Scale and EQ-5D-5L
throughout the study.
- Willing and able to provide written informed consent prior to any study-related
procedures and to comply with all study requirements.
- Females of reproductive potential must have a negative urine pregnancy test at
Screening/Baseline (to be confirmed by a serum pregnancy test taken on the last
treatment visit of their prior study). They are advised to use an effective,
non-hormonal method of contraception during treatment with pexidartinib and for 1
month after the last dose. Males with female partners of reproductive potential should
be advised to use an effective method of contraception during treatment with
pexidartinib and for 1 month after the last dose. Female partners of male patients
should concurrently use effective contraceptive methods (hormonal or non-hormonal).
Note: A female is considered of reproductive potential following menarche and until
becoming postmenopausal (no menstrual period for a minimum of 12 months) unless permanently
sterile (undergone a hysterectomy, bilateral salpingectomy or bilateral oophorectomy) with
a confirmed by follicle stimulating hormone (FSH) test level >40 mIU/mL.
- Male participants must not freeze or donate sperm starting at Screening and throughout
the study period, and for at least 5 half-lives or 1 month after the final study drug
administration, whichever is longer. Female participants must not donate, or retrieve
for their own use, ova from the time of Screening and throughout the study treatment
period, and for at least 1 month or 5 half-lives after the final study drug
administration, whichever is longer.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Participant has a clinically significant abnormality identified by the Investigator at
Screening on physical examination, laboratory tests, or electrocardiogram (ECG) which,
in the judgement of the Investigator, would preclude the participant's safe completion
of the study.
- Exposure to another investigational drug or current participation in other therapeutic
investigational procedures, besides pexidartinib studies, within 1 month prior to
start of study treatment. Any known contraindication to treatment with, including
hypersensitivity to, the study drug(s) or excipients in pexidartinib.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
20/10/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
7/07/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
32
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Chris O'Brien Lifehouse - Camperdown
Query!
Recruitment hospital [2]
0
0
Peter MacCallum Cancer Centre - East Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
3000 - East Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Massachusetts
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Missouri
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New York
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Oregon
Query!
Country [8]
0
0
Hungary
Query!
State/province [8]
0
0
Budapest
Query!
Country [9]
0
0
Italy
Query!
State/province [9]
0
0
Bologna
Query!
Country [10]
0
0
Italy
Query!
State/province [10]
0
0
Milano
Query!
Country [11]
0
0
Netherlands
Query!
State/province [11]
0
0
Leiden
Query!
Country [12]
0
0
Spain
Query!
State/province [12]
0
0
Barcelona
Query!
Country [13]
0
0
Spain
Query!
State/province [13]
0
0
Sevilla
Query!
Country [14]
0
0
Taiwan
Query!
State/province [14]
0
0
Taipei
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Daiichi Sankyo
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is designed to evaluate the discontinuation/re-treatment of pexidartinib therapy
in previously treated participants with tenosynovial giant cell tumor (TGCT).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04526704
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Team Leader
Query!
Address
0
0
Daiichi Sankyo
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04526704
Download to PDF